MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 67, Issue 9, 2008, Pages 1276-1281

  Rudwaleit, M ^a   Schwarzlose, S ^a   Hilgert, E S ^a   Listing, J ^b   Braun, J ^c   Sieper, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; CLINICAL INDICATOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SACROILIAC JOINT; SACROILIITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SACROILIAC JOINT; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50249188382     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073098     Document Type: Article

References (25)

1. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
3. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
4. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
5. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
6. Haibel H, Rudwaleit M, Brandt HC, Listing J, Grozdanovic Z, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis - clinical and magnetic resonance imaging results of a fifty-two week open label trial. Arthritis Rheum 2006;54:678-81.
7. van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun WE, et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial. Arthritis Rheum 2006;54:2136-46.
8. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
9. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
10. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
11. Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.
12. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF α treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
13. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
14. Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 2007;34:862-70.
15. van der Heijde D, Landewe R, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, et al. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 2007;34:871-3.
16. Landewe RB, Hermann KG, van der Heijde DM, Raraliakos X, Jurik AG, Lambert RG, et al. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. J Rheumatol 2005;32:2050-5.
17. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005;64:730-4.
18. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd edn. London, UK: Little 8 Brown, 1991: 69-152.
19. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
20. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
21. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
22. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondylarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502-9.
23. Puhakka KB, Jurik AG, Schiottz-Christensen B, Hansen GV, Egund N, Christiansen JV, et al. Magnetic resonance imaging of sacroiliitis in early seronegative spondylarthropathy. Abnormalities correlated to clinical and laboratory findings. Rheumatology (Oxford) 2004;43:234-7.
24. Jee WH, McCauley TR, Lee SH, Kim SH, Im SA, Ha KY. Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity. Magn Reson Imaging 2004;22:245-50.
25. Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC. MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR Am J Roentgenol 2006;187:1420-6.